Sign In
Buy DHR
$178.08
+1.97 (+1.12%)
At Close: Jun 03, 2026
SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations
07:00am, Monday, 02'nd Jun 2025
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #ZenoTOF--At ASMS 2025, SCIEX launches the ZenoTOF 8600 system, setting a new standard in accurate mass quantitation.
Danaher Partners With AstraZeneca to Support Precision Medicine
12:51pm, Friday, 30'th May 2025
DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient selection and making advanced tests accessible worldwide.
Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
04:30pm, Thursday, 29'th May 2025
Danaher has entered a partnership with AstraZeneca to scale precision medicine, including developing the next generation of AI-powered diagnostics This partnership aims to create a framework for rapid
CVS or DHR: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 26'th May 2025
Investors interested in stocks from the Medical Services sector have probably already heard of CVS Health (CVS) and Danaher (DHR). But which of these two stocks is more attractive to value investors?
Why Is Danaher (DHR) Down 4.8% Since Last Earnings Report?
12:36pm, Thursday, 22'nd May 2025
Danaher (DHR) reported earnings 30 days ago. What's next for the stock?
Here's Why Investors Should Consider Retaining Danaher Stock Now
10:55am, Thursday, 22'nd May 2025
DHR gains from strength across its businesses, acquired assets and shareholder-friendly policies. High long-term debt remains concerning.
-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivit
Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript)
03:32pm, Thursday, 15'th May 2025
Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mi
CVS vs. DHR: Which Stock Is the Better Value Option?
12:40pm, Friday, 09'th May 2025
Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for u
Danaher to Present at Bank of America Securities Healthcare Conference
04:15pm, Wednesday, 07'th May 2025
WASHINGTON , May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securi
Danaher Announces Quarterly Dividend
04:15pm, Tuesday, 06'th May 2025
WASHINGTON , May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common st
Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity
08:34am, Tuesday, 06'th May 2025
Danaher Corporation's intrinsic value is estimated at $213 per share, suggesting a 14% upside from the current price of $187, with a 12% margin of safety. Despite revenue growth driven by acquisitions
Danaher: Q1 Beat Fails To Trigger Guidance Upgrade
04:00am, Friday, 02'nd May 2025
Danaher's management appears to be strategically keeping the stock price depressed to complete its share buyback program and capitalize on lower acquisition target valuations. The company delivered be
Baron Health Care Fund Q1 2025 Top Contributors And Detractors
11:30am, Tuesday, 29'th Apr 2025
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa
Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow
10:07am, Tuesday, 29'th Apr 2025
Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmi
